O NYX-015 is a replication-selective adenovirus by virtue of deletion of the E1B-55 kDa region, thus minimizing viral replication in cells with normal p53 function, but enabling viral replication in p53 dysfunctional or mutated cells. 1, 2 Intravenous ONYX-015 administration produced tumor regression and improved survival in athymic mice bearing metastatic human tumor xenografts, and these benefits correlated with intratumoral viral replication. 3 Viral oncolytic activity in animals was further improved when combined with chemotherapy. [3] [4] [5] [6] In Phase I and II investigations in recurrent, refractory head and neck cancer patients, intratumoral injection of ONYX-015 alone produced a response rate of nearly 20% with demonstrable selective ONYX-015 replication in p53 mutant tumor tissues. [7] [8] [9] In chemotherapy-naive head and neck cancer patients, treatment with cisplatin, 5-fluorouracil (5-FU) and intratumorally injected ONYX-015, produced a 63% response rate, which compares favorably with the expected historical response rate of 35% for a similar population of patients. 10 Interestingly, in these patients, selective activity occurred even in patients without identifiable p53 mutations. In all these studies, no significant viral-related toxicity has been observed. [7] [8] [9] [10] We recently demonstrated that ONYX-015 could be administered safely as a single intravenous infusion in doses up to 2 Â 10 13 particles, and as a weekly infusion in doses ranging from 2 Â 10 10 to 2 Â 10 12 particles/infusion. 11 One patient who received a single infusion of 2 Â 10 13 particles developed moderate transaminitis. Otherwise, there were no dose-limiting toxicities in patients treated on a weekly basis, although mild to moderate transient fever was observed in all patients. The combination of ONYX-015 with weekly carboplatin (AUC2) and taxol (80 mg/m 2 ) did not alter toxicity. Evidence of intratumoral viral replication was suggested in one patient, but no tumor regression was observed.
The pilot study described here further examines the safety of intravenous administration of ONYX-015 in combination with low-dose IL-2 or chemotherapy. Two cohorts of patients were treated. In one, ONYX-015 was administered intravenously on a weekly basis (2 Â 10 12 particles) for 6 weeks in combination with weekly infusions of CPT11 (125 mg/m 2 /week), 5-FU (500 mg/ m 2 /week) and Decadron (10 mg i.v. pre-CPT11) for 4 weeks. In another cohort, ONYX-015 (2 Â 10 11 particles/ week) was administered intravenously weekly for 6 weeks in combination with low-dose rhIL-2 (1.1 Â 10 6 U s.q. daily for 5 days Â 4 weeks). The most significant organ uptake of virus following intravenous infusion occurs in the liver. The CPT11 regimen was chosen in order to provide an optimal regimen for colorectal cancer patients with hepatic metastasis. The low-dose IL-2 regimen was utilized to explore potential influence on viral-induced cytokines, which may be associated with anticancer immunity. Additionally, each regimen was chosen in order to also compare the effect of the immunosuppressive chemotherapy regimen to the immunostimulatory rhIL-2 regimen. Here, we report results comparing the safety and activity of each treatment regimen.
Methods

Test article
ONYX-015 is a chimeric human group C adenovirus (Ad2 and Ad5), originally constructed in the laboratory of Albert Berk. 12 A deletion between nucleotides 2496 and 3323 in the E1B region and a C to T transition at position 2022 in E1B generating a stop codon at the third codon position of the 55 kDa protein eliminate expression of the E1B 55 kDa gene in ONYX-015-infected cells. ONYX-015 was grown and titered on the human embryonic kidney cell line HEK293.
Study design
This was an open-label pilot trial study of ONYX-015 effectiveness and toxicity in combination with chemotherapy or with IL-2. Patients received ONYX-015 on days 1, 8, 15, 22, 29 , and 36 of each 6-week cycle. Chemotherapy was administered in combination with a viral dose of 2 Â 10 12 particles, while IL-2 treatment was given with a lower viral dose of 2 Â 10 11 particles.
ONYX-015 handling and processing
ONYX-015 is formulated as a sterile viral solution in TRIS buffer. The solution is supplied frozen (À201C) in single-use, plastic screw-cap vials. Each vial contains 0.5 ml of virus solution at a specified viral titer. Vialed virus solution was warmed and maintained at 2-81C during dilution and handling. Drug preparation was performed within 10 minutes before tumor infusion, using plastic syringes. Vials of ONYX-015 were opened and the appropriate volume of virus diluted to 10 ml with normal saline in a biologic safety cabinet. All waste items were disposed of in biohazard containers, which were then autoclaved and incinerated.
ONYX-015 intravenous infusion procedure
A single infusion of 10 ml of ONYX-015 with normal saline was administered over approximately 3-5 minutes, as specified in the product information sheet through a peripheral or central intravenous line (22-gauge catheter).
Chemotherapy dosing
Chemotherapy was administered to five patients in the study. A combination of CPT-11 (90 minutes intravenous infusion at 125 mg/m 2 ) followed by push doses of 5-FU (500 mg/m 2 ) and leucovorin (20 mg/m 2 ) was administered weekly on the same day as viral infusion. Premedications for chemotherapy were given per standard of practice for the clinic, including first 10 mg of dexamethasone followed by 100 mg of dolasetron, both by 30-minute intravenous infusion just before chemotherapy dosing. Each cycle consisted of chemotherapy being administered on days 1, 8, 15, and 22 followed by 2 weeks of rest.
IL-2 dosing
IL-2 treatment was administered subcutaneously to five patients at a dose of 1.1 million U/m 2 daily for 5 days each week. Dosing was initiated at the beginning of week 2 (day 8) of the cycle, the same day as the second virus treatment was administered. IL-2 treatments were given every week until the end of the cycle. IL-2 administration was limited to cycle 1.
Study population
Patients were treated at the Mary Crowley Medical Research Center of US Oncology located in the Sammons Cancer Center at Baylor University Medical Center, Dallas, Texas. Adult patients with advanced metastatic cancer who had failed one prior therapeutic regimen and for whom a curative therapy was not available were eligible. All patients were required to have histologically or cytologically confirmed carcinoma with Karnofsky performance status of X90%, life expectancy of X3 months, absolute neutrophils 41500/ml, hemoglobin 49 mg/dl, platelets 475,000/ml, creatinine o2.0 mg/dl, AST and ALT 43.0-fold upper limit of normal, PTT within normal limits, and total bilirubin o2.0 mg/dl. All patients consented to study participation on an IRBapproved informed consent form. Women and men of reproductive potential were required to use a reliable form of contraception.
Patients with the following conditions were excluded from the study: those with 450% liver replacement by tumor as determined radiographically; ongoing active infection (including human immunodeficiency virus); viral syndrome diagnosed within the last 2 weeks; chemotherapy within the last 3 weeks (6 weeks for nitrosourea or mitomycin-C); radiotherapy to tumor site within the last 4 weeks (if this was the only site of disease); treatment with any other investigational therapy within the last 4 weeks; concomitant hematological malignancy (i.e. chronic lymphocytic leukemia, non-Hodgkin's lymphoma); or an ongoing requirement for chronic immunosuppressive medication including glucocorticoid or cyclosporin, or chronic use of any such medication within the last 4 weeks. Pregnant or lactating females were excluded, and patients previously participating in research protocols involving administration of adenovirus vectors were excluded (with the exception of one compassionate use protocol patient).
Tumor response assessment
Up to five masses were measured for response assessment. A complete response (CR) was defined as complete disappearance of all tumors at all known sites, a partial response (PR) was defined as regression of the tumor mass (combined total of bidimensional measurements) by X50% but o100% with no growth of any individual lesion, stable disease (SD) was defined as a tumor mass decrease by o50% or increase in size by o25%, and progressive disease (PD) was defined as a X25% increase in tumor mass size or appearance of new lesions. Tumor response was assessed by CT scan of relevant organs each odd cycle. CT confirmation of all PRs and CRs 4 weeks after initial documentation of the response was required.
Adverse event definition
Severity of adverse events was assigned according to the NCIC-CTG Expanded Common Toxicity Criteria. A grade 1 or mild toxicity was considered a noticeable adverse event, but one that did not interfere with normal daily activities; a grade 2 or moderate adverse event was one that was sufficient to interfere with normal daily activities; a grade 3 or severe adverse event was incapacitating and caused the patient to be unable to perform daily activities (hospitalization was not necessarily required); a grade 4 or life-threatening adverse event posed an immediate risk of death as it occurred; and a grade 5 adverse event was fatal. If severe toxicity attributable to active viral replication had occurred, initiation of intravenous ribavirine therapy was recommended at 35 mg/kg divided into three doses given every 8 hours (the first day) followed by 25 mg/kg divided into three daily doses and given every 8 hours; however, no patients required ribavirine therapy.
Screening and pretreatment evaluation
Biopsies documenting carcinoma and evaluation of p53 status were taken prior to treatment with ONYX-015, although samples were not analyzed for p53 sequencing until after treatment initiation. Screening and pretreatment evaluation included a CT-scan of the chest, abdomen and pelvis as well as a chest X-ray (PA/lateral) within 21 days prior to treatment. A 12- Vital sign assessments were taken at baseline (45 minutes prior to ONYX-015 infusion 715 minutes), then repeated just before infusion and at the conclusion of the infusion, at the 15-minute mark, the 30-minute mark, and every 30 minutes thereafter through 150 minutes of time. Final vital signs were then measured 15 minutes following the 150-minute measurement. If any of the vital signs changed more than 20% from baseline after 2 hours, patients were retained, examined and vital signs taken until they returned to baseline values.
Procedures during the ONYX-015 treatment period
Day 1 (71 day) procedures included a brief physical examination directed to relevant signs, symptoms, vital signs, and weight. Blood for hematological tests and serum chemistry tests (including liver function), as well as serum for cytokine analysis (baseline and 6 hours, 71 hour, following injection of the virus) was drawn on day 1 for cycles 1 and 2 only. Cytokine analysis (24, 73 hours, following injection of the virus) was repeated on day 2 (71 day), in cycles 1 and 2. On day 3 (71 day), serum liver function tests were repeated and plasma for polymerase chain reaction (PCR) and antibody titer (only cycles 1 and 2) was obtained. Cytokine analysis (48, 73 hours, following injection of the virus) was done in cycles 1 and 2 only. On day 5 (71 day), serum liver function tests were repeated, and ultrasound-guided core needle biopsies of tumor tissue (metastatic liver lesions) were done on the first five patients in cycle 1 only to assess for presence of ONYX-015. Cytokine analysis (96, 73 hours, following the first injection of each cycle of the virus) was also done in cycles 1 and 2. On days 8-36 (72 days) of the second through sixth infusions of ONYX-015, hematological tests, serum chemistry tests including liver function, and physical examination were repeated weekly. Changes in concomitant medications and reporting of adverse events were summarized. A plasma sample was archived (cycles 1 and 2 only). Neutralizing antibody to ONYX-015 (only cycles 1 and 2), plasma for PCR, ONYX-015 titer (only cycles 1 and 2), and cytokine analysis (168, 73 hours, following the first injection of each cycle the virus) were done in cycles 1 and 2.
Pharmacokinetic venous blood draws
All patients had pharmacokinetic blood draws taken on day 1 of cycles 1 and 2. Blood was drawn at the start of the ONYX-015 infusion and at 5, 10, 30, 60, 90, 120, 180, and 360 minutes. Pharmacokinetics were repeated for the first dose of cycle 2 at time 0 prior to ONYX-015 infusion and at 30, 90, 120, and 360 minutes. Samples were also drawn prior to ONYX-015 infusion on days 8 and 15.
Off study assessment
Patients who completed their final cycle of ONYX-015 treatment or ended study for other reasons were withdrawn from study and had the following assessments completed: physical examination, determination of Karnofsky performance status, hematology, chemistry, urinalysis, documentation of adverse events, and documentation of concomitant medications.
Long-term follow-up
If patients went off study with an objective tumor response or stable disease (i.e. without tumor progression), an abdominal CT scan or ultrasound was taken every 6-8 weeks to follow for disease progression. All patients who went off study for any reason were followed for survival.
Statistical analysis
The study included two treatment cohorts, with five patients in each cohort. The data for each cohort were summarized with descriptive statistics, frequency tabulations, graphs, and data listings as appropriate.
P53 gene sequencing
Pretreatment tumor biopsies were taken for p53 sequencing performed at the John T Mallams Laboratory, Mary C Crowley Foundation, Baylor University Medical Center, Dallas, TX). DNA was extracted directly from sections of formalin-fixed paraffin-embedded needle biopsies. If necessary, tumor cells were microdissected from sections of paraffin-embedded tissue. DNA was isolated from tumor cells using phenol/chloroform extraction and ethanol precipitation, and the p53 gene was amplified in several fragments by PCR. The amplicons were purified by gel electrophoresis and analyzed using either the DNA Sequencing Kit (Boehringer Mannheim, Indianapolis, IN), or the ABI Model 310 automated sequencer. Accurate reading of the sequencing gels and the sequencer printout was confirmed by National Biosciences, Inc. (Plymouth, MN).
Quantitative PCR of ONYX-015 genome
A TaqMan-based assay was developed to quantitate the amount of ONYX-015 viruses in human plasma by Althea Technologies (San Diego, CA). The assay detects a 92 nt sequences from nt 2453 to 2544. The amplicon overlaps the E1B region deletion and includes the 8 bp Puc-derived linker insert. The central region of the TaqMan probe is homologous to the linker insert, making the probe specific to ONYX-015.
The lower limit of quantitation for the assay is 4.2 Â 10 4 particles of ONYX-015 per ml of plasma. The lower limit of detection is 1.05 Â 10 4 particles of ONYX-015 per ml of plasma. The presence of PCR inhibitors in the sample is monitored using an independent PCR reaction.
Patient samples were spiked with exogenous DNA to monitor the recovery in the extraction step and the presence of PCR inhibitors. A standard curve was prepared by serial dilutions of ONYX-015 virus from 2 Â 10 9 to 1.05 Â 10 4 vp/ml. Negative controls consisted of a plasma control without virus and a Type D adenovirus wild-type control. Viral DNA was extracted from patient samples, standards, and controls using QIAamp DNA mini kit. The amount of ONYX-015 viral DNA was quantitated by RT-PCR using the above described specific primer and probe.
The above method was modified for detection of ONYX-015 in human tissue. Up to 1 mg of DNA was tested per PCR. The standard curve consisted of ONYX-015 in the background of 1 mg of human placental DNA per reaction. The lower limit of quantitation for the assay is 26 genomes of ONYX-015 per mg of DNA. The lower limit of detection is 13 genomes of ONYX-015 per mg of DNA. A number of the samples tested contained PCR inhibitors of unidentified origin.
Cytokine analysis
Serum lL-6, tumor necrosis factor-a (TNF-a), IL-10, and interferon-g (g-IFN) levels were quantified by human cytokine-specific ELISA kits (R+D Quantikine kits; Minneapolis, MN). Post-treatment cytokine levels were compared with baseline levels. Patient peripheral blood was collected by venipuncture into Vacutainer tubes without anticoagulant, the serum extracted from clotted samples and stored at À801C. Serial post-treatment samples collected over each patient's treatment course were analyzed simultaneously (in triplicate), using cytokine-specific immunoassay reagents according to manufacturer's protocols. The calorimetric reaction was quantified as a function of light absorbence at 540 nm (optional density; OD) (SpectraMax 340; Molecular Devices, Sunnyvale, CA). Cytokine concentration was calculated in reference to a standard curve generated with four parameter logistic (4-PL) curve fit and OD values of known, graded concentrations of recombinant cytokine. The minimal detectable level of each cytokine is: IL-6: o0.7 pg/ml; TNF-a: o4.4 pg/ml; IL-10: o2 pg/ml; IFNg: o3 pg/ml.
Electron microscopy
Tissue samples were postfixed with osmium, dehydrated with ethanol, and embedded in plastic. Ultrathin sections were stained with uranyl acetate and lead citrate. Photography was done with a digital camera mounted on a LEO 906E electron microscope. The particles seen measured approximately 12.5 nm at a magnification of Â 158,000.
Determination of ONYX-015 neutralizing antibody titers
Neutralizing antibodies directed against adenovirus type 5/ONYX-015 were determined using a plaque-based assay. Briefly, patient plasma samples were serially diluted after heat inactivation at 551C for 30 minutes. Each plasma dilution was mixed with ONYX-015 stock at a titer prequalified to produce 15-20 plaques per 12-well dish in growth medium. The patient's sample-virus mixtures were inoculated for 1 hour at room temperature, and applied to 70-80% confluent JH293 cells in 12-well dishes. After 2 hours of incubation at 371C, 5% CO 2 , the plasma-virus mixture was replaced with 2 ml of 1.5% agarose. Plates were read on day 7 postinoculation by counting the number of plaques per well. The titer of neutralizing antibody for each sample was reported as the dilution of plasma that reduced the number of plaques to 60% of the number of plaques in the virus control without patient plasma.
The range of the neutralizing antibody titer assay is 1:20-1:81,920. The assay was performed at ONYX Pharmaceuticals.
Results
Patient profile
The age, sex, Karnofsky performance status, site of disease, histologic tumor type, prior treatments, and p53 status of the 10 treated patients are shown in Table 1 . These 10 patients received a total of 73 infusions of ONYX-015. The first five patients enrolled in the study received a total of 17 chemotherapy infusions (7 cycles) along with virus, and the next five patients received a total of 105 infusions of IL-2 (5 cycles) with virus. A summary of dosing schedules in all patients can be seen in Table 2 .
Adverse events
Two patients experienced grade 3 or grade 4 toxic events requiring dose interruption. No grade 3 or greater toxic event was related to the viral study drug; however, one patient (0010) experienced grade 3 neutropenia because of chemotherapy treatment and required dose interruption. All other incidents of grade 3 and 4 toxic events were related to progressive disease. Patient 0017 was hospitalized for a grade 3 increase in serum creatinine and BUN and grade 4 hyperkalemia. This was attributed to a previously undiagnosed monoclonal gammopathy. This patient was not treated further with ONYX-015. All grade 2-4 adverse events and relations to the study drug can be seen in Table 3 .
The most common toxicities related to ONYX-015 administration in both the chemotherapy and IL-2 cohorts were grade 2 fevers and chills. Five out of five patients who received this combination of ONYX-015+IL-2 developed grade 2 fever compared to three of five patients who received chemotherapy and decadron. Two patients in the chemotherapy cohort also experienced grade 2 nausea and vomiting related to chemotherapy. No patients demonstrated evidence of hepatotoxicity related to ONYX-015 infusion. Thus, the combination of ONYX-015 with chemotherapy or low dose IL-2 appeared to be well tolerated (Table 4) .
Tissue assessment of ONYX-015
Four of the first five patients underwent liver biopsy 5 days after the first intravenous infusion of ONYX-015. Sufficient tissue was available for quantitative PCR analysis of ONYX-015 genome in three patients (0012, 0013, 0014). In these three samples, ONYX-015 genome was detected at 1.09 Â 10 3 (0012), 4.41 Â 10 1 (0013), and 2.2 Â 10 3 (0014) genomes/ml. Histologic evaluation confirmed malignant tissue in patients 0012 and 0013, but the specimen for pathology from patient 0014 did not reveal the presence of malignant cells. The sample from patient 0010 was utilized for electron microscopy. Cytoplasmic hexagonal viral particles were seen in the ultrastructure of tumor cells, but not in benign hepatocytes. Samples from patient 0012 and 0013 were also reviewed by electron microscopy, but no viral particles were seen. Patient 0011 was unable to tolerate the liver biopsy procedure, so it was not performed. By protocol design, patients in cohort B did not undergo biopsy.
Neutralizing antibody response
Two patients (0017, 0021) had mild, elevated neutralizing antibodies at baseline (Fig 1) . All patients revealed marked antibody rises within 4 weeks after the first infusion of ONYX-015. In all cases but one (020), neutralizing antibody levels were significantly elevated 7 days following the first infusion. Antibody response did not differ between the two treatment cohorts. There was no apparent increase in adverse effects in patients with high neutralizing antibody titers.
Pharmacokinetics
Quantitative PCR testing on blood for ONYX-015 was performed at 30, 90, and 360 minutes after the first and fourth infusions of ONYX-015 (Table 5 ). For both first and second cycle treatments, the viral genome can be detected in the majority of patients within 30 minutes of administrations with a peak titer at less than 90 minutes. No differences in levels of circulating ONYX-015 genome were demonstrated between cycles 1 and 2 with either cohort. Viral genome concentration was lower in cohort B compared to cohort A, but this was likely related to the lower dose of ONYX-015 used in this cohort.
The persistence of circulating viral genome was assessed 2 and 7 days following i.v. infusion. ONYX-015 genome was detected 2 days after the first infusion in two (0012, 0013) of five patients measured. At 7 days after the first infusion two (013, 020) of the 10 patients demonstrated persistent detectable viral genome. ONYX-015 was also detectable on day 7 in two of nine measured patients after the fourth (0010, 0013) infusion. Interestingly, the highest quantities of circulating genome occurred in patient 0010 on day 7 of the fifth infusion (1.8 Â 10 7 genome particles/ ml). Patient 0010 had also demonstrated electron microscopic evidence of adenoviral particles in malignant cell cytoplasm. The quantity of viral genes in patient 10 at day 7 (of the fifth infusion) was also greater than the 6 hour genome quantity following the first and fourth ONYX-015 infusion, thereby suggesting viral replication, although we did not have a 6 hour measurement after the fifth infusion. Patient 0013 also had higher concentrations of genome/ml after the first infusion on day 7 ) and patient 20 had higher genome/ml on day 7 after the first infusion (6.07 Â 10 4 ) compared to the day 6 hour time point (2.02 Â 10 4 ). 
Serum cytokine response
Serum levels of the cytokines IL-6, TNF-a, IL-10, and IFN-g were assessed in all patients. Three of five patients (0010, 0013, 0014) in the first cohort had moderately increased IFN-g levels (7-44 pg/ml) as compared with baseline (o3 pg/ml) within 24 hours of viral infusion. The increase in g-IFN was transient and resolved by day 4. Serum IL6 levels also increased in four of five patients who received 10 12 viral particles at 6-72 hours postinfusion (21.1-34.4, 0.6-25.0, 18.3-29.9, 0.7-19.5 pg/ml). All patients in this cohort had moderately elevated serum IL-10 (7-22 pg/ml) that peaked at 72 hours postviral infusion and receded at day 4 (Fig 2) . Modest TNF increases occurred between 6 hours and day 2 in four of five patients, representing a 50-122% increase over pretreatment levels.
The five patients in the second cohort who received a lower dose of ONYX-015, (2 Â 10 11 particles) showed lower cytokine responses during the first week following viral infusion (Fig 1) . None of five patients had increased IFN-g levels and only a minority of patients produced elevated IL-6 (two of five); IL-10 (one of five) or TNF-a (one of five) following viral infusion. Similar to patients of the first cohort, elevated cytokines of all patients returned to baseline by day 4.
Treatment response
Tumor response is shown in Table 4 . Four patients achieved an optimal response of SD after at least one cycle of treatment, while six others demonstrated PD. Time to progression of disease as well as survival are also shown in Table 4 . Despite no evidence of early activity based on tumor response, several patients continue to demonstrate durable survival. One patient (0019) had a 450% decrease in Ca125 levels from 925 to 400 after cycle 1; however, CA125 levels returned to original baseline after cycle 2.
Discussion
Results of this pilot study further support our earlier observations that intravenous infusion of ONYX-015 is Pilot trial of intravenous infusion of a replication-selective adenovirus J Nemunaitis et al safe when administered in combination with other anticancer therapeutics. Previously, we demonstrated the safety of ONYX-015 in combination with carboplatin and taxol. Dose-limiting toxicity (transaminitis) in prior studies occurred at an infusion dose of 2 Â 10 13 particles. Therefore, the maximum dose used in this trial remained below the toxic dose level observed in our prior trial. The results of this pilot study do not demonstrate any evidence of enhanced adverse events when ONYX-015 was administered in combination with either CPT11, 5-FU and dexamethasone, or low-dose IL-2, although patients treated with the combination of IL-2 and ONYX-015 did develop more frequent transient low-grade fevers. This was easily managed with acetaminophen and did not interfere with continued treatment.
Despite reasonable safety, we found no significant evidence of activity. One patient with ovarian cancer did manifest a transient decrease in her CA125 levels, but this did not correlate with a decrease in bidimensional measurements of her tumor. Interestingly, lack of activity did not appear to be related to the lack of systemic exposure of ONYX-015 to malignant tissue. All patients demonstrated measurable viral genome concentrations in serum at 6 hours after infusion on day 1 or day 22. Further, three patients showed evidence of viral genome or intranuclear particles within malignant tissue 5 days after i.v. infusion of ONYX-015. Circulation of viral genome was not different between day 1 and day 22 (with the fourth ONYX-015 infusion); however, toxic events decreased with each viral infusion. This correlated with an increase in neutralizing antibody levels that generally occurred within 2 weeks of viral administration. A small number of patients in this pilot study showed evidence of persistent ONYX-015 genome in circulation at 2 and 7 days after the first infusion. These patients also demonstrated higher viral genome concentrations at 7 days following the first infusion compared to the 6-hour infusion concentration, again suggesting possible continued viral replication. However, given the dramatic and rapid rise of neutralizing antibodies in all patients receiving intravenous ONYX-015, combined with the lack of tumor response, it is likely that the persistent viral genome circulation at day 1 and day 22 represents noninfectious virus bound to neutralizing antibodies. 
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Further studies, such as assays to quantitate infectious virus particles in patients' serum will be needed to sort this out. Nevertheless, despite the lack of tumor response, it is encouraging that several patients demonstrated access of viral particles to malignant tissue following intravenous infusion.
In order for intravenous dosing of ONYX-015 to be utilized as an effective therapy, consistent delivery to, and uptake by, the tumor will be necessary. Preclinical studies indicate that more than 80% of ONYX-015 and other adenoviruses are taken up by the liver following intravenous administration. 13 One method of inhibition of normal cell uptake, particularly hepatic uptake, includes agents that disrupt macrophage function. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Infusion of silica and/or multilaminar liposomes delays elimination of adenoviral particles following infection in animal models.
14-28 A second factor influencing adenovirus uptake is the expression of coxsackie adenovirus receptor (CAR) on tumor cells. Since normal tissues express CAR, it can be hypothesized, that following i.v. administration, much of the circulating ONY-015 is taken up by normal tissue and is not exposed to malignant tissue. The ONYX-015 fiber-knob protein elements that mediate viral particle binding to CAR can also be modified with the use of bispecific antibodies targeting both fiber-protein elements and cancer-specific antigens (i.e., to human epithelial adhesion molecule). 29 Additionally, genetically modified viral DNA expressive of cancerspecific receptors (CEAy) could also be synthesized. Manipulation of CAR expression may also be possible. CAR expression and adenoviral entry is optimal during the M phase of mitosis. 30 Treatment with paclitaxel (a tubulin inhibitor) will synchronize cells at M phase via stabilization of microtubules, 31, 32 suggesting that the combination of paclitaxel and ONYX-015 may be reasonable to test further. Another major factor influencing the efficacy and toxicity of adenovirus agents is the immune response to adenovirus administration and replication. Adenovirus-mediated gene transfection in immunodeficient mice or immunocompetent animals treated with immunosuppressive agents results in prolonged transgene expression. This remains to be evaluated. Reduction of viral-specific neutralizing antibodies, either through inhibition of production or removal of existing antibodies may also facilitate malignant cell uptake of functional virus. Specific measures which directly modulate neutralizing antibody levels could involve plasma pheresis, inhibition of B cell function (anti-CD20 antibody therapy), and/or desensitization. 58, 59 ONYX-015 is constructed with a partially deleted E3 region expressive of proteins GP19K and 11.6 but not 14.7 or 10.4/14.5. GP19K inhibits MHC class I expression and adenoviral specific cytotoxic T-lymphocyte killing. Protein 11.6 induces lysis of the infected cell to release 11 particles and rhIL-2 starting at day 8 of treatment (patient 0017-0021, n ¼ 5). Absolute serum level changes ranged from a minimum of o2-3.5 pg/ml (baseline) to 6.9-21.8 pg/ ml (day 2).
Pilot trial of intravenous infusion of a replication-selective adenovirus J Nemunaitis et al progeny of the infected cell enabling infection of adjacent cell. Proteins 10.4 and 14.5 modulate cell surface receptors (specifically to Fas) which predispose the host cell to eradication and protein 14.7 [60] [61] [62] [63] [64] [65] inhibits TNF-amediated cell death. ONYX-015 as a result of the E3 deleted region may have greater sensitivity to toxic effects of TNF-a. Little is understood regarding the significance of the role of TNF in the clearance of viral particles. TNF gene knockout mice have prolonged presence of nonreplicating adenoviral vectors and expression of the transgene product is prolonged compared to normal TNF expressive mice. 67, 68 Interestingly, several wild-type viruses actually produce soluble binding proteins specific to TNF. [69] [70] [71] [72] [73] [74] [75] Viral-produced TNF binding proteins have a similar extracellular domain as the human TNF receptor, but lack both the membrane anchor and cytoplasmic domains. [76] [77] [78] Given the evidence that TNF induction may affect adenoviral survival, particularly with ONYX-015 which does not contain the E3 region expressive of 14.7 protein, we have initiated a pilot trial testing the combination of ONYX-015 with Enbrel (soluble TNF receptor) in cancer patients.
Our findings of elevated TNF-a, IFN-g, IL-6, and IL-10 particularly among patients who received 1 Â 10 12 particles are consistent with the thesis of immune activation that was identified in our previously published study. 11 Compared with the delayed kinetics of viralneutralizing antibody production, upregulation of IL-6 followed by TNF-a, IFN-g, and IL-10 indicate the induction of acute proinflammatory cytokines that initiate the host's triphasic immune response. 66 The higher magnitude of increase in serum IL-6, TNF-a, IFN-g, and IL-10 in patients who received 1 Â 10 12 particles (as compared with second cohort patients who received 1 Â 10 11 particles) further suggests a viral dosage-dependent effect on immune activation. Adjuvant IL-2 treatment did not contribute to this observed difference between the two patient cohorts, since IL-2 infusion did not initiate until day 8 of treatment.
Others have also explored intravenous infusion of replicating cancer selective viruses. 79 In all, 79 patients with refractory cancer were administered multiple intravenous infusions of PV701, a selectively replicating attenuated Newcastle disease virus. Clinical results revealed a similar toxicity profile to our patients (i.e. transient fever), except transient hypotension was defined as the dose-limiting toxicity. Toxic effect was considered to be potentially related to TNF induction. Clinical response was demonstrated in a small number of patients.
Finally, in preclinical models, replication-competent adenoviruses enhance delivery of transgene products to a greater degree than similar nonreplicating vectors. Specifically, delivery of herpes simplex type I thymidine kinase and cytosine deaminase genes correlate with greater transgene expression and antitumor effect when delivered via a replicating adenoviral vector as opposed to a nonreplicating adenoviral vector. 80, 81 Additionally, other gene modified viruses variant from ONYX-015 (i.e. ONYX-411) have been shown preclinically to have greater replicative capacity by 1000-fold while monitoring similar tumor specificity. 82 Therefore, if safety data continue to accumulate as shown in this pilot study and others, ONYX-015, or other similar oncolytic viruses could potentially be tested as systemic ''cancer selective'' gene delivery vehicles.
